Mankind Pharma's Q1 FY26 results show a revenue increase of 24.5% to INR 3,570 Cr, with EBITDA margin at 23.8%; an interim dividend of Rs 1 per share has been approved. The report is based on consolidated financial statements for the quarter ending June 30, 2025.